These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26827956)

  • 1. The Role of Vitamin D₃ in the Development and Neuroprotection of Midbrain Dopamine Neurons.
    Orme RP; Middleditch C; Waite L; Fricker RA
    Vitam Horm; 2016; 100():273-97. PubMed ID: 26827956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurorestoration.
    Airavaara M; Voutilainen MH; Wang Y; Hoffer B
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1(0 1):S143-6. PubMed ID: 22166416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression.
    Orme RP; Bhangal MS; Fricker RA
    PLoS One; 2013; 8(4):e62040. PubMed ID: 23626767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of glial cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo organotypic brain slice Parkinson's disease models.
    Ucar B; Humpel C
    Brain Res Bull; 2019 Jul; 149():86-95. PubMed ID: 31004735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D: preventive and therapeutic potential in Parkinson's disease.
    Liu Y; Li YW; Tang YL; Liu X; Jiang JH; Li QG; Yuan JY
    Curr Drug Metab; 2013 Nov; 14(9):989-93. PubMed ID: 24160295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noncoding RNAs and Midbrain DA Neurons: Novel Molecular Mechanisms and Therapeutic Targets in Health and Disease.
    Pascale E; Divisato G; Palladino R; Auriemma M; Ngalya EF; Caiazzo M
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32899172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of endoplasmic reticulum stress in Parkinson's disease.
    Tsujii S; Ishisaka M; Hara H
    Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H2O2- or l-DOPA-injured dopaminergic neurons trigger the release of soluble mediators that up-regulate striatal GDNF through different signalling pathways.
    Fonseca CP; Gama S; Saavedra A; Baltazar G
    Biochim Biophys Acta; 2014 Jul; 1842(7):927-34. PubMed ID: 24632468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salusin-β mediate neuroprotective effects for Parkinson's disease.
    Chang Y; Yoo J; Kim H; Park HJ; Jeon S; Kim J
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1428-1433. PubMed ID: 30017195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective Effects of 7, 8-dihydroxyflavone on Midbrain Dopaminergic Neurons in MPP
    He J; Xiang Z; Zhu X; Ai Z; Shen J; Huang T; Liu L; Ji W; Li T
    Sci Rep; 2016 Oct; 6():34339. PubMed ID: 27731318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain.
    Cui X; Pelekanos M; Liu PY; Burne TH; McGrath JJ; Eyles DW
    Neuroscience; 2013 Apr; 236():77-87. PubMed ID: 23352937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
    Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
    Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson's Disease.
    Ghanta MK; Elango P; L V K S B
    Curr Pharm Des; 2020; 26(37):4738-4746. PubMed ID: 32065086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.
    Shadfar S; Kim YG; Katila N; Neupane S; Ojha U; Bhurtel S; Srivastav S; Jeong GS; Park PH; Hong JT; Choi DY
    Mol Neurobiol; 2018 Jan; 55(1):554-566. PubMed ID: 27975170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current disease modifying approaches to treat Parkinson's disease.
    Lindholm D; Mäkelä J; Di Liberto V; Mudò G; Belluardo N; Eriksson O; Saarma M
    Cell Mol Life Sci; 2016 Apr; 73(7):1365-79. PubMed ID: 26616211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease.
    Vogt Weisenhorn DM; Giesert F; Wurst W
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):8-26. PubMed ID: 27206718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Molecular Insights into the Active Engagement of Cannabinoids in the Therapy of Parkinson's Disease: A Novel and Futuristic Approach.
    Jain V; Behl T; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Meraya AM; Najmi A
    Neurotox Res; 2023 Feb; 41(1):85-102. PubMed ID: 36567416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
    Grondin R; Gash DM
    J Neurol; 1998 Nov; 245(11 Suppl 3):P35-42. PubMed ID: 9808338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of FBXO7 results in a Parkinson's-like dopaminergic degeneration via an RPL23-MDM2-TP53 pathway.
    Stott SR; Randle SJ; Al Rawi S; Rowicka PA; Harris R; Mason B; Xia J; Dalley JW; Barker RA; Laman H
    J Pathol; 2019 Oct; 249(2):241-254. PubMed ID: 31144295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy.
    Stoof JC; Winogrodzka A; van Muiswinkel FL; Wolters EC; Voorn P; Groenewegen HJ; Booij J; Drukarch B
    Eur J Pharmacol; 1999 Jun; 375(1-3):75-86. PubMed ID: 10443566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.